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IL-25 Enhances HSV-1 Replication by Inhibiting
Filaggrin Expression, and Acts Synergistically with Th2
Cytokines to Enhance HSV-1 Replication
Byung Eui Kim1, Lianghua Bin1, Young-Min Ye1,2, Preveen Ramamoorthy3 and Donald Y.M. Leung1,4
Atopic dermatitis (AD) is characterized by epidermal barrier defects and recurrent microbial skin infections. AD
patients with a history of eczema herpeticum (ADEHþ ) have more severe skin disease and more highly T helper
type 2 (Th2)–polarized immune responses as compared with uncomplicated AD (ADEH ). However, the
mechanisms linking epidermal barrier defects and viral skin infection are not well understood. Recently, it has
been reported that interleukin-25 may play a role in augmenting Th2 responses. We examined protein expression
of IL-25 in the skin biopsies from normal subjects (n¼ 10), ADEH (n¼ 18), ADEHþ (n¼ 7), and psoriasis (n¼ 9).
IL-25 expression was increased in the skin from ADEH , ADEHþ , and psoriasis as compared with normal skin,
and was significantly greater in lesional ADEHþ skin than in lesional ADEH skin. Importantly, we
demonstrated that IL-25 enhances herpes simplex virus (HSV)-1 and vaccinia virus replication by inhibiting
filaggrin expression, and IL-25 acts synergistically with IL-4 and IL-13 to enhance HSV-1 replication in vitro. In
contrast, IFN-g inhibited HSV-1 replication in vitro. In addition, we demonstrate that filaggrin is a critical protein
to inhibit HSV-1 replication because filaggrin small interfering RNA knockdown enhances HSV-1 replication
in vitro. Filaggrin breakdown products, however, inhibited HSV-1 replication in vitro.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory skin disease
that affects up to 20% of children and 3% of adults (Bieber,
2010; Zheng et al., 2011). Epidermal barrier defects and
recurrent microbial skin infections are characteristic findings
in AD (Irvine et al., 2011; Kim and Leung, 2012). Previously,
our laboratory reported that T helper type 2 (Th2) cytokines
are overexpressed in AD skin (Hamid et al., 1994) and
downregulate epidermal barrier proteins (Kim et al., 2008;
Howell et al., 2009, 2011). In addition, we have reported
that Th2 cytokines promote disseminated viral skin infections
such as eczema herpeticum (EH) by inhibiting the expression
of antimicrobial peptides (AMPs) in AD skin (Howell et al.,
2006a, b, 2011). It is known that AD patients with a history of
EH (ADEHþ ) have more Th2-polarized immune responses
(Beck et al., 2009) and a higher prevalence of filaggrin (FLG)-
null mutations compared with patients with AD not
complicated by EH, i.e., ADEH (Gao et al., 2009). FLG
gene mutations only affect a minority of AD patients.
Therefore, additional mechanisms linking epidermal barrier
defects and susceptibility to viral skin infections remain to be
elucidated.
Recently, it has been proposed that IL-25 might play an
important role in augmenting Th2 responses in allergic
diseases (Barlow et al., 2011; Hvid et al., 2011). IL-25 and
its receptor IL-17Rh1 are expressed in AD skin (Lee et al.,
2001; Hvid et al., 2011), and IL-25 downregulates FLG mRNA
(Hvid et al., 2011). There have been no previous studies,
however, investigating whether IL-25 modulation of epidermal
barrier proteins enhances viral replication. Moreover, it has
not been investigated whether Th2 cytokines act synergi-
stically with IL-25 to modulate epidermal barrier protein
expression and to enhance viral replication.
In this study, we examined IL-25 expression in human skin
and compared the relative effects of IL-25, Th2 cytokines, and
IFN-g on the expression of filaggrin. In addition, we demon-
strate that IL-25 functionally enhances herpes simplex virus-1
(HSV-1) and vaccinia virus (VV) replication by inhibiting
filaggrin expression, and found that Th2 cytokines act syner-
gistically with IL-25 to enhance HSV-1 replication via their
inhibitory effects on filaggrin expression.
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RESULTS
IL-25 expression is increased in skin with AD and psoriasis
A recent study showed that IL-25 protein is expressed in AD
skin (Hvid et al., 2011). However, there have been no
previous studies demonstrating protein expression of IL-25 in
normal subjects versus patients with ADEH and ADEHþ .
In this study, we examined the protein expression of IL-25 in
skin biopsies from 10 normal subjects, 18 ADEH patients,
and 7 ADEHþ patients. In addition, we examined the
expression of IL-25 in the skin from nine psoriasis patients as
a disease control. As shown in Figure 1a, IL-25 protein
expression was increased in the skin of patients with ADEH ,
ADEHþ , and psoriasis compared with skin from normal
subjects. The composite data for IL-25 immunostaining in all
samples are shown in Figure 1b. The staining intensity of IL-25
was significantly increased in lesional and nonlesional skin
from ADEH (Po0.05 and Po0.05), ADEHþ (Po0.01 and
Po0.01), and psoriasis (Po0.05 and Po0.05, respectively)
patients compared with skin from normal subjects. However,
it is important to note that the staining intensity of IL-25 in
lesional ADEHþ skin was significantly increased (Po0.05)
compared with lesional ADEH skin. Furthermore, we
performed genotypic analysis for common filaggrin mutations
including R501X, 2282del4, R2447X, S3247X, and 3702delG
in all samples. In all, 1 of 10 normal subjects (10%), 6 of 18
ADEH subjects (33.3%), and 1 of 7 ADEHþ subjects
(14.3%) showed heterozygotic mutations, and no homozygo-
tic mutations were reported.
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Figure 1. The expression of IL-25 in human skin. (a) Representative paraffin-embedded skin biopsies from normal subjects (n¼ 10) and patients with
ADEH (n¼ 18), ADEHþ (n¼7), and psoriasis (n¼ 9) stained for IL-25 (red) are shown. ADEHþ , atopic dermatitis patients with a history of eczema
herpeticum; ADEH , atopic dermatitis patients without a history of eczema herpeticum. Wheat germ agglutinin–conjugated FITC (green) stained the cytoskeleton.
Images were collected at original magnification  400. Arrows point to IL-25 expression. Bar¼ 50mm. (b) The mean fluorescence intensity of IL-25 is shown
in the epidermis of each biopsy. *Po0.05 and **Po0.01.
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IL-25 inhibits the expression of filaggrin and acts synergistically
with Th2 cytokines to inhibit filaggrin expression
A recent study found that IL-25 inhibits mRNA expression of
FLG (Hvid et al., 2011), but these investigators did not study
protein expression of filaggrin. Therefore, we examined
whether IL-25 modulates both mRNA and protein expression
of filaggrin. In addition, we compared the effects of IL-25 with
those of Th2 cytokines (IL-4 and IL-13) on filaggrin expression.
We differentiated normal human keratinocytes (KCs) with
1.3 mmol l1 CaCl2 in various concentrations of IL-25, Th2
cytokines, IFN-g, or a combination of IL-25 and Th2 cytokines
for 5 days. Gene expression of FLG was significantly inhibited
(Po0.05) by 50 ng ml1 of IL-25 (4.35±0.18 ng of FLG per ng
of 18S) compared with media alone (6.02±0.33 ng of FLG per
ng of 18S) (Figure 2a). In addition, the gene expression of FLG
was significantly decreased in KCs treated with a combination
of IL-25 and Th2 cytokines (1.27±0.22 ng) as compared with
KCs treated with IL-25 (Po0.001, 4.35±0.18 ng) or Th2
cytokines (Po0.05, 2.25±0.20 ng) alone. Moreover, this
was confirmed at the protein level using western blot analysis
(Figure 2b and c). We also performed FLG genotypic analysis
for the KCs we used. None of the KCs genotyped had the
mutations of R501X, 2282del4, R2447X, S3247X, and
R3702delG.
IL-25 enhances HSV-1 replication and acts synergistically with
Th2 cytokines to enhance HSV-1 replication
Both IL-25 and Th2 cytokines are overexpressed in the skin of
patients with ADEH and ADEHþ , and it is known that Th2
cytokines enhance viral replication (Howell et al., 2006b,
2007). As IL-25 is known to enhance Th2 responses, we
investigated whether IL-25 also enhances viral replication. We
differentiated KCs with 1.3 mmol l1 CaCl2 in the presence or
absence of IL-25, Th2 cytokines, IFN-g, or a combination of
IL-25 and Th2 cytokines for 5 days. Then, the cells were
incubated with HSV-1 or VV for an additional 24 hours.
Indeed, we found that the gene expression of HSV-1 was
significantly increased (Po0.05) in KCs pretreated with IL-25
(1.12±0.06 ng) as compared with KCs without IL-25
pretreatment (0.83±0.01 ng; Figure 3a). Similarly, VV gene
expression was significantly increased in KCs pretreated with
IL-25 as compared with KCs without IL-25 pretreatment (data
not shown). In addition, HSV-1 expression was further
increased in KCs pretreated with a combination of IL-25 and
Th2 cytokines (2.18±0.13 ng) as compared with cells pre-
treated with IL-25 (1.12±0.06 ng, Po0.01) or Th2 cytokines
(1.80±0.07 ng, Po0.05) alone. In contrast, HSV-1 expression
was significantly decreased (Po0.001) in KCs pretreated with
IFN-g (0.12±0.02 ng) compared with cells without IFN-g
pretreatment (0.83±0.01 ng). We also found that VV staining
intensity was increased in organotypic skin pretreated
with IL-25 compared with organotypic skin without IL-25
pretreatment (Figure 3b).
It is known that Th2 cytokines enhance viral replication by
inhibiting expression of AMPs such as cathelicidin (LL-37) and
human b-defensin 3 (HBD-3) (Howell et al., 2006b, 2007).
Therefore, we further investigated whether IL-25 modulates
the expression of LL-37 and HBD-3 using the same samples.
As shown in Figure 3c and d, the gene expression of LL-37 and
HBD-3 was significantly upregulated in KCs stimulated
with HSV-1 (LL-37: 0.18±0.02 ng, Po0.05; HBD-3:
8.98±0.43 ng, Po0.05) compared with cells treated with
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Figure 2. IL-25 downregulates filaggrin expression, and acts synergistically
with T helper type 2 (Th2) cytokines to inhibit filaggrin (FLG) expression.
Keratinocytes (KCs) were stimulated in the various concentrations of IL-25, Th2
cytokines (50 ng ml1 of IL-4 and 50 ng ml 1 of IL-13), a combination of IL-25
(50 ng ml1) and Th2 cytokines, or IFN-g (20ng ml1) for 5 days. (a) The gene
expression of FLG was examined using real-time reverse-transcriptase–PCR
(RT–PCR). (b) The protein expression of filaggrin was evaluated by western blot
analysis. (c) Relative expression of profilaggrin in 250 kDa and bigger
profilaggrin bands. Data from one representative experiment of three
independent experiments performed are shown. *Po0.05, **Po0.01, and
***Po0.001.
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Figure 3. IL-25 enhances viral replications, and acts synergistically with T helper type 2 (Th2) cytokines to enhance viral replication. Keratinocytes (KCs) were
differentiated in the absence or presence of IL-25 (50 ng ml1), Th2 cytokines (50 ng ml1 of IL-4 and 50 ng ml 1 of IL-13), a combination of IL-25 and Th2
cytokines, or IFN-g (20ng ml1) for 5 days. Then, the cells were incubated with herpes simplex virus 1 (HSV-1; multiplicity of infection (MOI), 0.1) for
an additional 24 hours. The gene expression of (a) HSV-1, (c) cathelicidin (LL-37), and (d) human b-defensin 3 (HBD-3) was examined using real-time
reverse-transcriptase–PCR (RT–PCR). (b) Organotypic skin sections were stained for vaccinia virus (VV; red) and the cytoskeleton (green). Arrows point to vaccinia
virus. Bar¼50mm. Data from one representative experiment of three independent experiments performed are shown. *Po0.05, **Po0.01, and ***Po0.001.
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Figure 4. The filaggrin (FLG) silencing enhances herpes simplex virus 1 (HSV-1) replication. Keratinocytes (KCs) were transfected with scrambled small interfering
RNA (siRNA) or FLG siRNA, and the cells were differentiated for 5 days. Then, the cells were incubated with HSV-1 (multiplicity of infection (MOI), 0.1) for
an additional 24 hours. (a) The gene expression of FLG in the KCs was examined using real-time reverse-transcriptase–PCR (RT–PCR). (b) The protein expression
of filaggrin and profilaggrin was evaluated by western blot technique. (c) The gene expression of HSV-1 was examined using real-time RT–PCR. (d) Viral
plaque formation was determined by using the viral plaque assay. Data from one representative experiment of three independent experiments performed are
shown. *Po0.05 and **Po0.01.
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media alone (LL-37: 0.06±0.01 ng; HBD-3: 6.11±0.84 ng).
HSV-1-induced gene expression of LL-37 and HBD-3 was
significantly inhibited in cells treated with Th2 cytokines (LL-
37: 0.10±0.01 ng, Po0.05; HBD-3: 5.64±0.62 ng, Po0.05)
compared with cells treated with IL-25 (LL-37: 0.17±0.01 ng;
HBD-3: 9.64±0.38 ng) or HSV-1 alone (LL-37: 0.18±0.02 ng,
HBD-3: 8.98±0.43 ng). However, IL-25 did not inhibit HSV-1-
induced gene expression of LL-37 and HBD-3, suggesting that
IL-25 does not enhance HSV-1 replication by inhibiting AMPs.
FLG silencing enhances HSV-1 replication
It has been suggested that filaggrin is a critical protein to
maintain epidermal integrity and plays an important role
in preventing Staphylococcus aureus infection (O’Regan
et al., 2008; Miajlovic et al., 2010). Therefore, we further
investigated the importance of filaggrin against HSV-1
replication using a small interfering RNA (siRNA) technique.
We transfected KCs with scrambled siRNA or FLG siRNA, and
the KCs were differentiated in the presence or absence of IL-25
for 5 days. The cells were then stimulated with HSV-1 for an
additional 24 hours. As shown in Figure 4a, FLG gene
expression was significantly inhibited (Po0.05) in KCs trans-
fected with FLG siRNA (11.30±1.28 ng) compared with cells
transfected with scrambled siRNA (22.52±3.09 ng). This was
confirmed at the protein level using western blot technique
(Figure 4b). Importantly, HSV-1 gene expression was signifi-
cantly enhanced (Po0.01) in KCs transfected with FLG siRNA
(18.72±1.79 ng) compared with cells transfected with
scrambled siRNA (6.99±0.24 ng; Figure 4c). We further
investigated using HSV-1 viral plaque-forming assay. As
shown in Figure 4d, HSV-1 plaques were significantly
(Po0.05) increased in KCs transfected with FLG siRNA
(49.00±4.73103 plaques per ml) compared with cells
transfected with scrambled siRNA (25.33±5.81103 plaques
per ml). However, HSV-1 gene expression was not affected by
IL-25 in KCs transfected with FLG siRNA (Figure 4c).
Filaggrin breakdown products induce acidic environment and
inhibit HSV-1 replication
Filaggrin breakdown products such as urocanic acid (UCA)
and pyrrolidone carboxylic acid (PCA) are important in
maintaining an acidic environment in the skin (O’Regan
et al., 2008; Kezic et al., 2012), and an acidic pH inhibits
the entry of HSV-1 into cells (Rosenthal et al., 1989). In
addition, it has been shown that UCA and PCA inhibit growth
of S. aureus (Miajlovic et al., 2010). Therefore, we further
investigated whether UCA and PCA induce acidic pH
conditions and inhibit HSV-1 replication. We incubated KCs
with HSV-1 in the presence of various concentrations of UCA
and PCA for 24 hours. The pH of KCs culture media was
decreased in a dose-dependent manner (data not shown). In
addition, as shown in Figure 5a, HSV-1 gene expression was
significantly inhibited (Po0.01) by UCA and PCA with a
concentration as low as 5 mmol l1 (0.48±0.04 ng) compared
with media alone (0.78±0.09 ng). We further investigated
whether an acidic environment inhibits HSV-1 replication.
We incubated KCs with HSV-1 in the presence of various
concentrations of hydrochloric acid for 24 hours. Importantly,
HSV-1 gene expression was significantly (Po0.01) inhibited
by medium with pH 6.25±0.09 (16.14±2.26 ng) compared
with medium with pH 7.78±0.19 (35.14±3.46 ng; Figure 5b).
DISCUSSION
In this study, we found that IL-25 is increased in lesional and
nonlesional skin of patients with ADEH , ADEHþ , and
psoriasis as compared with normal skin. This finding confirms
a previous study that IL-25 is expressed in the skin from normal
subjects, and patients with AD and psoriasis (Hvid et al., 2011).
Importantly, we also demonstrated that the level of IL-25 protein
expression is higher in lesional ADEHþ skin than it is in
lesional ADEH skin, suggesting that IL-25 may play a role in
the enhancement of HSV-1 replication in ADEHþ skin. On the
other hand, viral infection is not common in psoriasis skin
(Christophers and Henseler, 1987) even though IL-25 expression
is increased in psoriasis skin compared with normal subjects.
This could be explained that psoriasis skin does not have
increased Th2 cytokines, which inhibit expression of AMPs and
epidermal barrier proteins, and shows increased Th1 cytokines
known to inhibit viral replication (Leung et al., 2011).
On the basis of our current data and previous data
(Hamid et al., 1994), both IL-25 and Th2 cytokines such as
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Figure 5. Filaggrin breakdown products and an acidic environment inhibit
herpes simplex virus 1 (HSV-1) replication. Keratinocytes (KCs) were
incubated with HSV-1 (multiplicity of infection (MOI), 0.1) in the presence of
various concentrations of (a) urocanic acid (UCA) and pyrrolidone carboxylic
acid (PCA) or (b) hydrochloric acid for 24 hours. The gene expression of
HSV-1 was examined using real-time reverse-transcriptase–PCR (RT–PCR).
Data from one representative experiment of three independent experiments
performed are shown. **Po0.01 and ***Po0.001.
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IL-4 and IL-13 are overexpressed in AD skin. However,
ADEHþ patients are most Th2 polarized. As Th2 cytokines
reduce the expression of epidermal barrier proteins (Kim et al.,
2008; Howell et al., 2009), we examined whether IL-25
modulates expression of filaggrin. We confirmed and
extended the previous study showing that IL-25 inhibits
mRNA expression of FLG (Hvid et al., 2011) by using both
quantitative reverse-transcriptase–PCR and western blot
analysis. Filaggrin is produced as profilaggrin then breaks
down into filaggrin monomers. Therefore, profilaggrin
will be decreased first by IL-25 as we showed in current
data. However, filaggrin monomer was not inhibited by IL-25
in our data. It is possible that prolonged incubation of KCs
with IL-25 for 45 days is needed before filaggrin monomer
would also be reduced. In addition, there might be
posttranslational events of filaggrin, which are hard to
demonstrate in in vitro experiments. In addition, we
compared the inhibitory effects of IL-25 on filaggrin
expression with those of Th2 cytokines. We showed that
IL-25 is less potent than Th2 cytokines. However, IL-25 could
potentially play an important role in inhibiting filaggrin
expression in vivo because IL-25 promotes production of
Th2 cytokines in vivo (Fort et al., 2001).
This study studied whether IL-25 enhances both HSV-1 and
VV replication. Importantly, IL-25 enhanced both HSV-1 and
VV replication, but did not modulate the expression of AMPs,
suggesting that IL-25 does not enhance HSV-1 and VV
replication by inhibiting the expression of AMPs. Therefore,
we further investigated how IL-25 enhances viral replication
using a siRNA technique. Of note, we found that HSV-1
replication was significantly enhanced in KCs transfected with
FLG siRNA. These data strongly support that filaggrin is a
critical epidermal protein involved in the inhibition of HSV-1
replication. Moreover, these data are consistent with previous
data that FLG KO mice are susceptible to VV infection (Geha
and Oyoshi, 2012) and data that null mutations in the FLG
gene are highly associated with ADEHþ (Gao et al., 2009). In
addition, we showed that IL-25 did not affect the HSV-1
replication in the KCs transfected with FLG siRNA, suggesting
that IL-25 enhances HSV-1 replication by inhibiting filaggrin
expression, and not by others.
We found that IL-25 acts synergistically with Th2 cytokines
to inhibit filaggrin expression and enhance HSV-1 replication.
This synergism is explained by the different mechanisms in
which IL-25 and Th2 cytokines act. IL-25 inhibits filaggrin by
activating NF-kB (Lee et al., 2001). In contrast, Th2 cytokines
inhibit expression of AMPs (Albanesi et al., 2007; Howell
et al., 2006b, 2011) and epidermal barrier proteins (Kim et al.,
2008; Sehra et al., 2010) through signal transducer and
activator of transcription 6 activation. Therefore, IL-25
modulates filaggrin in a manner different than Th2 cytokines
and acts synergistically with Th2 cytokines to inhibit filaggrin
expression and enhance HSV-1 replication in vitro. In addition,
as Th2 cytokines inhibit both filaggrin and AMPs, they are
more potent than IL-25 in vitro to enhance HSV-1 replication.
Our data also showed that IFN-g inhibits HSV-1 replication.
This finding is consistent with previous data that IFN-g induces
AMPs (Nomura et al., 2003; Albanesi et al., 2007).
To understand how filaggrin deficiency enhances HSV-1
replication, we incubated KCs with HSV-1 in the presence of
the filaggrin breakdown products. We found that UCA and
PCA induce an acidic environment, and an acidic environ-
ment inhibits HSV-1 replication. These findings show consis-
tency with previous data that filaggrin end products play an
important role to maintain acidic environment in the skin
(O’Regan et al., 2008; Kezic et al., 2012) and inhibit S. aureus
infection (Rosenthal et al., 1989; Miajlovic et al., 2010).
Rosenthal et al. (1989) reported that mild acidic environ-
ment inhibit viral entry into cells by blocking fusion of the
viral envelope with a cellular membrane. We do not have
direct evidence that filaggrin itself inhibits HSV-1 replication.
However, our data suggest that filaggrin deficiency modifies
local pH and enhances viral entry into keratinocytes. Therefore,
our data strongly suggest that filaggrin is a key epidermal
barrier protein to prevent HSV-1 infection in skin modulated
by IL-25, as well as IL-4 and IL-13.
In summary, this study demonstrates that IL-25 enhances
viral replication by inducing filaggrin deficiency. Furthermore,
PCA and UCA inhibit viral replication. Therefore, maintaining
normal filaggrin expression may be important for control of
viral skin infections, and topical application of PCA and UCA
could be a useful strategy for prevention of viral infection in
AD skin.
MATERIALS AND METHODS
Subjects
Subjects included 10 healthy persons with no history of skin diseases,
18 patients with ADEH , 7 patients with ADEHþ , and 9 patients
with psoriasis. None of the patients had previously received systemic
corticosteroids or cyclosporine, and none had received topical
corticosteroid or calcineurin inhibitors for at least 1 week before
enrollment. These studies were conducted according to the Declara-
tion of the Helsinki Principles and were approved by the Institutional
Review Board at National Jewish Health in Denver. All subjects gave
written informed consent before participation in these studies. From
the upper arm or antecubital area, 2 mm punch skin biopsies were
obtained. The skin biopsies were submerged in 1 ml of 10% buffered
formalin for immunohistochemistry.
Viruses
The Wyeth/ACAM2000 strain of vaccinia virus was obtained from the
Centers for Disease Control and Prevention (Atlanta, GA). HSV-1 (VR-
733) was purchased from ATCC (Manassas, VA).
KC culture
KCs were grown in serum-free EpiLife cell culture medium (Cascade
Biologics, Portland, OR) as described previously (Kim et al., 2011).
KCs were seeded in 24-well plate overnight and then treated with
various cytokines, PCA and UCA, or hydrochloric acid for 24 hours or
5 days, followed by incubation with HSV-1 (multiplicity of infection
(MOI), 0.1) or VV (MOI, 0.1) for 24 hours.
Organotypic skin culture
To produce organotypic skin culture using KCs, human dermal
fibroblast (Invitrogen, Carlsbad, CA) and culture insert (BD
Bioscience, Bedford, MA) were used. Human dermal fibroblasts were
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cultured in Medium 106 (Invitrogen). A mixture of fibroblasts and
dermal collagen type I (Advanced BioMatrix, San Diego, CA) were
used as a dermal equivalent. KCs were plated on the dermal
equivalent and cultured for 5 days in the presence or absence of IL-
25 for 5 days. Then, the cells were incubated with VV (MOI, 0.1) for
an additional 24 hours.
Genotypic analysis of filaggrin
DNAs were isolated from human skin biopsies and KCs using a Roche
MagNA Pure Compact with Nucleic Acid Isolation Kit I (Roche,
Indianapolis, IN). The DNAs were subjected to genotyping using
Taqman MGB probes (Roche) on a Roche Light Cycler 480 instru-
ment. The fluorescent signals are collected in both VIC and FAM
emission wavelengths by the LightCycler 480 real-time PCR machine
(Roche) when the TaqMan MGB probes hybridized to the comple-
mentary sequence are cleaved by Fast Start Taq DNA polymerase
during extension.
RNA preparation and real-time reverse-transcriptase–PCR
RNeasy Mini Kits (Qiagen, Valencia, CA) were used according to the
manufacturer’s protocol to isolate RNA from cell cultures. RNA was
reverse transcribed into complementary DNA and analyzed by
reverse-transcriptase–PCR by using an ABI Prism 7000 sequence
detector (Applied Biosystems, Foster City, CA), as described earlier
(Nomura et al., 2003). Primers and probes for human 18S, FLG, HSV-
1, VV, HBD-3, and LL-37 were purchased from Applied Biosystems.
Immunofluorescent staining
Paraffin-embedded tissues from human skins or organotypic skin
sections were stained as described earlier (Kim et al., 2011). Slides
were stained with a polyclonal rabbit anti-human IL-25 antibody
(1:500 dilution, EMD Millipore, Billerica, MA) or a monoclonal
mouse anti-A27L antibody direct against VV (1:500, Abcam,
Cambridge, MA).
Western blot analysis
Proteins were separated on an SDS-polyacrylamide gel, 4–20% (Bio-
Rad, Hercules, CA) and blotted. The blots were blocked and incubated
with primary antibodies. The mAbs against filaggrin (1:200 dilution,
Vector Laboratories, Burlingame, CA) and b-actin (1:1,500 dilution;
Sigma Chemical, St Louis, MO) were used as primary antibodies. The
densities of profilaggrin and b-actin were measured using ImageJ,
version 1.43 (National Institutes of Health, Bethesda, MD).
siRNA silencing experiment
FLG and the control siRNA duplexes were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The KCs were plated in 24-well
plates the day before transfection. A total volume of 5 pmol siRNA
duplexes was transfected into each well of cells using Lipofectamine
2000 according to the manufacturer’s instructions (Invitrogen). The
following day, the cells were switched to serum-free EpiLife Medium
containing 1.3 mM CaCl2 to differentiate. After differentiating for
5 days, the cells were then incubated with HSV-1 (MOI, 0.1) for
24 hours.
Viral plaque assays
Cells and culture supernatants were harvested together after 24 hours
of viral incubation to assess the production of infectious viral
particles. Cells were disrupted by three freeze–thaw cycles. Viral
yields were determined by using a titration plaque assay, as
previously described (Howell et al., 2006c).
Statistical analysis
Statistical analysis was conducted using GraphPad Prism, version
4.03 (San Diego, CA). Statistical differences in gene expression or
protein expression between multiple groups were determined using
one-way analysis of variance, and significant differences were
determined by the Tukey–Kramer test. In cases where two groups
were compared, data were analyzed using unpaired t-test.
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